West Oak Capital’s VistaGen Therapeutics VTGN Stock Holding History

West Oak Capital’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-17	Closed	-$750	–	329
2018 Q4	$750	Hold	17	–	–	﹤0.01%	324
2018 Q3	$725	Hold	17	–	–	﹤0.01%	349
2018 Q2	$685	Hold	17	–	–	﹤0.01%	318
2018 Q1	$464	Buy	+17	New	+$632	﹤0.01%	341

Other funds holding VTGN

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

West Oak Capital's VTGN Position: Q1 2019 in Review

West Oak Capital sold out of VistaGen Therapeutics (VTGN) in Q1 2019, closing a stake of 17 shares — an estimated $750 sold.

West Oak Capital first reported a position in VTGN in Q1 2018 and held it in 4 quarters. The position peaked at $750 in Q4 2018. 25 funds tracked by Wall St. Rank hold VTGN as of Q1 2019.

West Oak Capital reported no remaining VistaGen Therapeutics position as of Q1 2019 after selling out during the quarter.
West Oak Capital sold 17 VistaGen Therapeutics shares in Q1 2019, an estimated $750.
West Oak Capital first reported a position in VistaGen Therapeutics in Q1 2018 and held it in 4 quarters.
West Oak Capital's VistaGen Therapeutics position peaked at $750 in Q4 2018.
25 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2019.

Based on West Oak Capital's 13F filing for Q1 2019, filed 3 Apr 2019.